Meeting
2015 Gastrointestinal Cancers Symposium
A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab refractory esophagogastric (EG) cancer.
Authors
Yelena Yuriy Janjigian
Memorial Sloan Kettering Cancer Center, New York, NY
Yelena Yuriy Janjigian , Geoffrey Yuyat Ku , David H. Ilson , Michelle S. Boyar , Marinela Capanu , Joanne F. Chou , David Paul Kelsen , Tooba Imtiaz , Michael F. Berger , Efsevia Vakiani
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Translational Research
Clinical Trial Registration Number
NCT01522768
Citation
J Clin Oncol 33, 2015 (suppl 3; abstr 59)
DOI
10.1200/jco.2015.33.3_suppl.59
Abstract #
59
Poster Bd #
B9
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
A phase II study of afatinib in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab-refractory esophagogastric (EG) cancer.
First Author: Yelena Yuriy Janjigian
Poster
2021 ASCO Annual Meeting
Imaging HER2-positive metastatic esophagogastric cancer with 89Zr-trastuzumab PET and 18F-FDG PET.
First Author: Melissa Amy Lumish
Poster
2024 ASCO Gastrointestinal Cancers Symposium
HLX22 plus HLX02 and XELOX for first-line treatment of HER2-positive locally advanced or metastatic gastric/gastroesophageal junction cancer: A randomized, double-blind, multicenter phase 2 study.
First Author: Jin Li
Poster
2022 ASCO Annual Meeting
Trastuzumab plus FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14).
First Author: Choong-kun Lee